Alterity Therapeutics Ltd Asset Resilience Ratio

Latest as of December 2025: 86.44%

Alterity Therapeutics Ltd asset resilience ratio. Alterity Therapeutics Ltd (ATH) has an Asset Resilience Ratio of 86.44% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ATH defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

AU$49.20 Million
≈ $34.81 Million USD Cash + Short-term Investments

Total Assets

AU$56.92 Million
≈ $40.27 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Alterity Therapeutics Ltd (2006–2025)

Asset resilience ratio of Alterity Therapeutics Ltd from 2006 to 2025. This chart shows how Alterity Therapeutics Ltd's Asset Resilience Ratio has changed over time. Read ATH current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Alterity Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Alterity Therapeutics Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$49.20 Million 86.44%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$49.20 Million 86.44%

Asset Resilience Insights

  • Very High Liquidity: Alterity Therapeutics Ltd maintains exceptional liquid asset reserves at 86.44% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Alterity Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare Alterity Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 36.07%
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
3SBio Inc
F:83B
Biotechnology 10.64%

Alterity Therapeutics Ltd Asset Resilience Ratio by Year (2006–2025)

Alterity Therapeutics Ltd asset resilience ratio by year from 2006 to 2025. The table below shows the annual Asset Resilience Ratio data for Alterity Therapeutics Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 16.30% AU$7.50 Million
≈ $5.31 Million
AU$46.03 Million
≈ $32.57 Million
--
2024-06-30 0.00% AU$0.00
≈ $0.00
AU$19.22 Million
≈ $13.60 Million
--
2022-06-30 84.15% AU$34.81 Million
≈ $24.63 Million
AU$41.36 Million
≈ $29.27 Million
+0.44pp
2021-06-30 83.71% AU$28.12 Million
≈ $19.89 Million
AU$33.59 Million
≈ $23.76 Million
+82.26pp
2020-06-30 1.45% AU$192.71K
≈ $136.35K
AU$13.30 Million
≈ $9.41 Million
-70.88pp
2019-06-30 72.33% AU$14.40 Million
≈ $10.19 Million
AU$19.91 Million
≈ $14.09 Million
-9.09pp
2018-06-30 81.41% AU$15.25 Million
≈ $10.79 Million
AU$18.73 Million
≈ $13.25 Million
-5.33pp
2017-06-30 86.74% AU$21.93 Million
≈ $15.52 Million
AU$25.28 Million
≈ $17.89 Million
--
2016-06-30 0.00% AU$0.00
≈ $0.00
AU$33.73 Million
≈ $23.86 Million
--
2015-06-30 0.36% AU$152.60K
≈ $107.98K
AU$41.83 Million
≈ $29.60 Million
-0.23pp
2007-06-30 0.59% AU$45.63K
≈ $32.28K
AU$7.72 Million
≈ $5.46 Million
+0.18pp
2006-06-30 0.41% AU$42.40K
≈ $30.00K
AU$10.43 Million
≈ $7.38 Million
--
pp = percentage points

About Alterity Therapeutics Ltd

AU:ATH Australia Biotechnology
Market Cap
$2.04 Billion
AU$2.88 Billion AUD
Market Cap Rank
#18617 Global
#579 in Australia
Share Price
AU$0.27
Change (1 day)
-7.02%
52-Week Range
AU$0.01 - AU$0.71
All Time High
AU$0.71
About

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more